<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809079</url>
  </required_header>
  <id_info>
    <org_study_id>2016017</org_study_id>
    <nct_id>NCT02809079</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients</brief_title>
  <acronym>MONICA</acronym>
  <official_title>Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease of the central&#xD;
      nervous system that leads to blindness and paralysis. Since disability accrues incrementally&#xD;
      related to attacks, attack prevention with immunosuppressive therapy is the mainstay of&#xD;
      preventing disability. However, there is no standard immunosuppressive treatment strategy for&#xD;
      NMO relapse prevention. In a previous study, the investigators provided evidence supporting&#xD;
      the use of azathioprine plus a low dose corticosteroid as an effective strategy which is&#xD;
      associated with a reduction in the risk of relapse in Chinese patients with NMO, but&#xD;
      azathioprine has bone marrow suppression and other side effects. Mycophenolate mofetil (MMF)&#xD;
      is a new immunosuppressant with rapid onset, fewer side effects and other advantages. In&#xD;
      recent years, MMF has been used in different immune-related neurological diseases; some&#xD;
      literature shown the possible efficacy of MMF in NMO treatment.&#xD;
&#xD;
      In this research, a multi-center (Third Affiliated Hospital of Sun Yat-sen University,&#xD;
      Zhongshan Ophthalmic Centre of Sun Yat-sen University, Nangfang Hospital of Southern Medical&#xD;
      University) study will carry out to evaluate the efficacy and safety of mycophenolate mofetil&#xD;
      therapy in NMO spectrum disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized relapse rate day 360</measure>
    <time_frame>day 360 after staring treatment</time_frame>
    <description>Patients come back for follow-up visit on day 360 after staring treatment, and annualized relapse rate was evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>expanded disability status scale</measure>
    <time_frame>day 1, 14, 30, 90, 180, 270, 360 after staring treatment</time_frame>
    <description>Patients come back for follow-up visit on day 1, 14, 30, 90, 180, 270, 360 after staring treatment, and expanded disability status scale was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hauser scale</measure>
    <time_frame>day 1, 14, 30, 90, 180, 270, 360 after staring treatment</time_frame>
    <description>Patients come back for follow-up visit on day 1, 14, 30, 90, 180, 270, 360 after staring treatment, and Hauser scale was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vision scale</measure>
    <time_frame>day 1, 14, 30, 90, 180, 270, 360 after staring treatment</time_frame>
    <description>Patients come back for follow-up visit on day 1, 14, 30, 90, 180, 270, 360 after staring treatment, and vision scale was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesions in brain and spinal cord</measure>
    <time_frame>day 1, 14, 30, 90, 180, 270, 360 after staring treatment</time_frame>
    <description>Patients come back for follow-up visit on day 1, 14, 30, 90, 180, 270, 360 after staring treatment, lesions in brain and spinal cord were evaluated by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>day 1, 14, 30, 90, 180, 270 after staring treatment</time_frame>
    <description>Patients come back for follow-up visit on day 1, 14, 30, 90, 180, 270 after staring treatment, and annualized relapse rate was evaluated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuromyelitis Optica Spectrum Disorders</condition>
  <condition>Mycophenolate Mofetil</condition>
  <condition>Efficacy and Safety</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil plus prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycophenolate mofetil 500mg Bid and prednisone 10mg Qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil 500mg Bid</description>
    <arm_group_label>Mycophenolate mofetil plus prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>prednisone 10mg Qd</description>
    <arm_group_label>Mycophenolate mofetil plus prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet the 2006 Wingerchuk diagnostic criteria;&#xD;
&#xD;
          -  NMO-immunoglobulin G seropositive;&#xD;
&#xD;
          -  Between 18 to 65 years old;&#xD;
&#xD;
          -  Relapse: more than 2 relapses in recent 2 years; more than 1 relapses in recent 1&#xD;
             years;&#xD;
&#xD;
          -  Expanded disability status scale: expanded disability status scale≤7.0, and visual&#xD;
             acuity ≥20 / 100 at least in one eye&#xD;
&#xD;
          -  Understand the purpose and procedures of this study, and written informed consent is&#xD;
             obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Using immunosuppressive agents and other drugs affect evaluation, and drug withdrawal&#xD;
             less than 3 months;&#xD;
&#xD;
          -  Patients with any of the following diseases: transaminases elevation exceed 2 times of&#xD;
             the normal upper limit; white blood cell &lt;4 × 109 / L, Hemoglobin &lt;80g / L, platelet&#xD;
             &lt;100 × 109 / L;&#xD;
&#xD;
          -  With serious cardiovascular, liver, kidneys and other vital organs and blood,&#xD;
             endocrine system diseases, cancer history;&#xD;
&#xD;
          -  With immunodeficiency, uncontrolled infection and active gastrointestinal diseases&#xD;
             (such as gastric ulcer, etc.);&#xD;
&#xD;
          -  Pregnancy, breast-feeding women and male or female who plans to conceive recently;&#xD;
&#xD;
          -  Allergy to mycophenolate mofetil and prednisone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Qiu, Medical PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Falcini F, Trapani S, Ricci L, Resti M, Simonini G, de Martino M. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford). 2006 Jul;45(7):913-5. Epub 2006 Apr 25.</citation>
    <PMID>16638802</PMID>
  </results_reference>
  <results_reference>
    <citation>Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, Kim HJ. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014 Nov;71(11):1372-8. doi: 10.1001/jamaneurol.2014.2057.</citation>
    <PMID>25199960</PMID>
  </results_reference>
  <results_reference>
    <citation>Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009 Sep;66(9):1128-33. doi: 10.1001/archneurol.2009.175.</citation>
    <PMID>19752302</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>June 19, 2016</last_update_submitted>
  <last_update_submitted_qc>June 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Wei Qiu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>share by publications and meetings</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

